MEDISTIM ASA (MEDI.OL) Fundamental Analysis & Valuation

OSL:MEDI • NO0010159684

Current stock price

233 NOK
+4 (+1.75%)
Last:

This MEDI.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. MEDI.OL Profitability Analysis

1.1 Basic Checks

  • MEDI had positive earnings in the past year.
  • MEDI had a positive operating cash flow in the past year.
  • MEDI had positive earnings in each of the past 5 years.
  • MEDI had a positive operating cash flow in each of the past 5 years.
MEDI.OL Yearly Net Income VS EBIT VS OCF VS FCFMEDI.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 24.10%, MEDI belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
  • MEDI's Return On Equity of 33.99% is amongst the best of the industry. MEDI outperforms 98.41% of its industry peers.
  • MEDI has a Return On Invested Capital of 29.26%. This is amongst the best in the industry. MEDI outperforms 98.41% of its industry peers.
Industry RankSector Rank
ROA 24.1%
ROE 33.99%
ROIC 29.26%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MEDI.OL Yearly ROA, ROE, ROICMEDI.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • MEDI's Profit Margin of 22.75% is amongst the best of the industry. MEDI outperforms 95.24% of its industry peers.
  • MEDI's Profit Margin has improved in the last couple of years.
  • The Operating Margin of MEDI (28.04%) is better than 95.24% of its industry peers.
  • MEDI's Operating Margin has been stable in the last couple of years.
  • With an excellent Gross Margin value of 81.68%, MEDI belongs to the best of the industry, outperforming 93.65% of the companies in the same industry.
  • MEDI's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.04%
PM (TTM) 22.75%
GM 81.68%
OM growth 3Y-0.79%
OM growth 5Y1.29%
PM growth 3Y-0.6%
PM growth 5Y3.55%
GM growth 3Y1.4%
GM growth 5Y0.69%
MEDI.OL Yearly Profit, Operating, Gross MarginsMEDI.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MEDI.OL Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MEDI is creating value.
  • MEDI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDI.OL Yearly Shares OutstandingMEDI.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
MEDI.OL Yearly Total Debt VS Total AssetsMEDI.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • The Debt to FCF ratio of MEDI is 0.20, which is an excellent value as it means it would take MEDI, only 0.20 years of fcf income to pay off all of its debts.
  • MEDI's Debt to FCF ratio of 0.20 is amongst the best of the industry. MEDI outperforms 95.24% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that MEDI is not too dependend on debt financing.
  • MEDI's Debt to Equity ratio of 0.08 is amongst the best of the industry. MEDI outperforms 84.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.2
Altman-Z N/A
ROIC/WACC3.42
WACC8.55%
MEDI.OL Yearly LT Debt VS Equity VS FCFMEDI.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MEDI has a Current Ratio of 3.34. This indicates that MEDI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MEDI (3.34) is better than 84.13% of its industry peers.
  • A Quick Ratio of 2.21 indicates that MEDI has no problem at all paying its short term obligations.
  • The Quick ratio of MEDI (2.21) is better than 80.95% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 2.21
MEDI.OL Yearly Current Assets VS Current LiabilitesMEDI.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MEDI.OL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.62% over the past year.
  • The Earnings Per Share has been growing by 18.02% on average over the past years. This is quite good.
  • Looking at the last year, MEDI shows a very strong growth in Revenue. The Revenue has grown by 24.38%.
  • Measured over the past years, MEDI shows a quite strong growth in Revenue. The Revenue has been growing by 14.02% on average per year.
EPS 1Y (TTM)53.62%
EPS 3Y11.79%
EPS 5Y18.02%
EPS Q2Q%79.18%
Revenue 1Y (TTM)24.38%
Revenue growth 3Y12.46%
Revenue growth 5Y14.02%
Sales Q2Q%20.61%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.18% on average over the next years. This is quite good.
  • Based on estimates for the next years, MEDI will show a quite strong growth in Revenue. The Revenue will grow by 11.61% on average per year.
EPS Next Y10.06%
EPS Next 2Y9.27%
EPS Next 3Y17.18%
EPS Next 5YN/A
Revenue Next Year18.2%
Revenue Next 2Y13.27%
Revenue Next 3Y11.61%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MEDI.OL Yearly Revenue VS EstimatesMEDI.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
MEDI.OL Yearly EPS VS EstimatesMEDI.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. MEDI.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.75 indicates a quite expensive valuation of MEDI.
  • MEDI's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of MEDI to the average of the S&P500 Index (26.91), we can say MEDI is valued inline with the index average.
  • MEDI is valuated quite expensively with a Price/Forward Earnings ratio of 29.82.
  • Based on the Price/Forward Earnings ratio, MEDI is valued a bit more expensive than 60.32% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of MEDI to the average of the S&P500 Index (23.68), we can say MEDI is valued slightly more expensively.
Industry RankSector Rank
PE 26.75
Fwd PE 29.82
MEDI.OL Price Earnings VS Forward Price EarningsMEDI.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • MEDI's Enterprise Value to EBITDA ratio is in line with the industry average.
  • Based on the Price/Free Cash Flow ratio, MEDI is valued a bit cheaper than the industry average as 74.60% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.31
EV/EBITDA 18.97
MEDI.OL Per share dataMEDI.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDI does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of MEDI may justify a higher PE ratio.
  • MEDI's earnings are expected to grow with 17.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.66
PEG (5Y)1.48
EPS Next 2Y9.27%
EPS Next 3Y17.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. MEDI.OL Dividend Analysis

5.1 Amount

  • MEDI has a Yearly Dividend Yield of 3.85%.
  • MEDI's Dividend Yield is rather good when compared to the industry average which is at 1.20. MEDI pays more dividend than 96.83% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, MEDI pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.85%

5.2 History

  • On average, the dividend of MEDI grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • MEDI pays out 68.76% of its income as dividend. This is not a sustainable payout ratio.
  • MEDI's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP68.76%
EPS Next 2Y9.27%
EPS Next 3Y17.18%
MEDI.OL Yearly Income VS Free CF VS DividendMEDI.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
MEDI.OL Dividend Payout.MEDI.OL Dividend Payout, showing the Payout Ratio.MEDI.OL Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDI.OL Fundamentals: All Metrics, Ratios and Statistics

MEDISTIM ASA

OSL:MEDI (4/10/2026, 1:44:01 PM)

233

+4 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-27
Earnings (Next)05-07
Inst Owners60.88%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap4.27B
Revenue(TTM)699.77M
Net Income(TTM)159.21M
Analysts87.5
Price Target316.2 (35.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.85%
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DP68.76%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.57%
PT rev (3m)19.23%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9.67%
Revenue NY rev (3m)9.67%
Valuation
Industry RankSector Rank
PE 26.75
Fwd PE 29.82
P/S 6.11
P/FCF 22.31
P/OCF 22.31
P/B 9.12
P/tB 9.12
EV/EBITDA 18.97
EPS(TTM)8.71
EY3.74%
EPS(NY)7.81
Fwd EY3.35%
FCF(TTM)10.45
FCFY4.48%
OCF(TTM)10.45
OCFY4.48%
SpS38.16
BVpS25.54
TBVpS25.54
PEG (NY)2.66
PEG (5Y)1.48
Graham Number70.75
Profitability
Industry RankSector Rank
ROA 24.1%
ROE 33.99%
ROCE 37.92%
ROIC 29.26%
ROICexc 49.58%
ROICexgc 49.58%
OM 28.04%
PM (TTM) 22.75%
GM 81.68%
FCFM 27.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-0.79%
OM growth 5Y1.29%
PM growth 3Y-0.6%
PM growth 5Y3.55%
GM growth 3Y1.4%
GM growth 5Y0.69%
F-Score7
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.2
Debt/EBITDA 0.18
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 90.27%
Profit Quality 120.33%
Current Ratio 3.34
Quick Ratio 2.21
Altman-Z N/A
F-Score7
WACC8.55%
ROIC/WACC3.42
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)104.92%
Profit Quality(5y)105.73%
High Growth Momentum
Growth
EPS 1Y (TTM)53.62%
EPS 3Y11.79%
EPS 5Y18.02%
EPS Q2Q%79.18%
EPS Next Y10.06%
EPS Next 2Y9.27%
EPS Next 3Y17.18%
EPS Next 5YN/A
Revenue 1Y (TTM)24.38%
Revenue growth 3Y12.46%
Revenue growth 5Y14.02%
Sales Q2Q%20.61%
Revenue Next Year18.2%
Revenue Next 2Y13.27%
Revenue Next 3Y11.61%
Revenue Next 5YN/A
EBIT growth 1Y49.68%
EBIT growth 3Y11.57%
EBIT growth 5Y15.49%
EBIT Next Year18.24%
EBIT Next 3Y20.16%
EBIT Next 5YN/A
FCF growth 1Y61.78%
FCF growth 3Y27.52%
FCF growth 5Y20.91%
OCF growth 1Y33.87%
OCF growth 3Y19.07%
OCF growth 5Y20.91%

MEDISTIM ASA / MEDI.OL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDISTIM ASA (MEDI.OL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDI.OL.


Can you provide the valuation status for MEDISTIM ASA?

ChartMill assigns a valuation rating of 3 / 10 to MEDISTIM ASA (MEDI.OL). This can be considered as Overvalued.


What is the profitability of MEDI stock?

MEDISTIM ASA (MEDI.OL) has a profitability rating of 8 / 10.


Can you provide the expected EPS growth for MEDI stock?

The Earnings per Share (EPS) of MEDISTIM ASA (MEDI.OL) is expected to grow by 10.06% in the next year.


Is the dividend of MEDISTIM ASA sustainable?

The dividend rating of MEDISTIM ASA (MEDI.OL) is 6 / 10 and the dividend payout ratio is 68.76%.